In the last decade, Chimeric Antigen Receptor (CAR)-T cell therapy has emerged as a
promising immunotherapeutic approach to fight cancers. This approach consists of …

Over the past decade, lung cancer treatment has undergone a major paradigm shift. A
greater understanding of lung cancer biology has led to the development of many effective …

Lung cancer accounts for a relatively high proportion of malignant tumors. As the most
prevalent type of lung cancer, non-small cell lung cancer (NSCLC) is characterized by high …

There has been a rapid progress in developing genetically engineered T cells in recent
years both in basic and clinical cancer studies. Chimeric antigen receptor (CAR)-T cells …

Chimeric antigen receptor (CAR)-T cell therapy is a new class of cellular immunotherapies,
which has made great achievements in the treatment of malignant tumors. Despite …

Nowadays, lung cancer is still the deadliest oncological disease in the world. Among them,
non-small cell lung cancer (NSCLC) accounts for 80%∼ 85% of all lung cancers, and its 5 …

Chimeric antigen receptor (CAR) T cell therapy has achieved unprecedented clinical
success against hematologic malignancies. However, the transition of CAR-T cell therapies …

Cancer is characterized by uncontrolled cell growth, disrupted regulatory pathways, and the
accumulation of genetic mutations. These mutations across different types of cancer lead to …

Chimeric antigen receptor T (CAR-T) cell therapy has exhibited a substantial clinical
response in hematological malignancies, including B-cell leukemia, lymphoma, and multiple …

The high primary resistance incidence and unavoidable secondary resistance are the major
clinical obstacle to lasting long-term benefits in Non-small-cell lung cancer (NSCLC) …